Research paper

Outcomes of adults who received liver transplant as young children

Sunitha Vimalesvaran, Lara Neves Souza, Maesha Deheragoda, Marianne Samyn, Jemma Day, Anita Verma, Hector Vilca-Melendez, Mohamed Rela, Nigel Heaton, Anil Dhawan*

* Corresponding author.

Keywords: pediatric Liver transplantation long-term biopsychosocial outcomes

ABSTRACT

Background: Patient and graft survival 20-years after pediatric liver transplantation (pLT) are excellent. In children, attainment of normal growth, education and social adaptation to be an independent adult are equally important. This is particularly relevant for children who receive liver transplant at a young age, where infantile-onset liver disease, surgery and immunosuppression can adversely affect growth and neurodevelopment. The aim of this study was to evaluate the long-term physical and psychosocial outcomes of pLT recipients with normal graft function. We coin the term ‘meaningful survival’. Methods: We performed a cross-sectional study of pLT recipients who received transplants between 1985 and 2004. A 20-year evaluation of physical health (growth, renal function), mental wellbeing and social outcomes (substance abuse, adherence, education, employment) was performed. All patients included were considered to have normal graft function.

Findings: Eighty-four patients met study criteria. Median age at transplantation was 1.3 years (IQR 0.7–3.3 years), with median duration of follow-up of 20.2 years (18.0–23.5). At median of 20-years, 19 patients (23%) had chronic renal dysfunction and 3 patients (4%) had a BMI of >30 (mean 20.4). Evaluation of long-term psychosocial outcomes demonstrated 22 patients (26%) with mental health disorders. Substance abuse was lower than national average. 62 patients (74%) were in education, employment or training. Overall, only 26% of our cohort achieved a composite outcome of ‘meaningful survival’.

Interpretation: This is the largest reported long-term study of biopsychosocial outcomes of pLT recipients with normal graft function, with follow-up upon completion of physical growth and senior school education. Importantly, despite normal liver function, many patients did not demonstrate ‘meaningful survival’. We must refocus our efforts towards better understanding the long-term outcomes of children. A ‘meaningful survival’ rather than mere survival should be our goal.

Funding: None.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Pediatric liver transplantation (pLT) is the standard of care for children with end stage liver disease and liver-based metabolic defects. Patient survival at 20 years is >80% [1]. As our survival rates consistently improve into adulthood, it is important that we ensure not only physical wellbeing but also preserve mental health, school performance and ultimately employment, so post-transplant recipients are able to lead a ‘meaningful’ and socially inclusive life [2]. The ‘meaningful survival’ we should strive for our pLT recipients is one where recipients are in a state of reasonable physical, mental and social wellbeing, and not merely the absence of disease.

We should be mindful that long-term complications might become more evident as patient survival approaches over 20 years. Some of this is possibly secondary to the early post-transplant period, whilst some are cumulative side effects of immunosuppression and sub-optimal adherence to treatment [3]. Individual genetic make-up and background health can affect long-term outcomes as well [4].
End-organ damage is an important aspect to consider as patient survival improves. Renal disease tends to be the main cause of morbidity and mortality after liver transplantation in adults [5]. The long-term impact of numerous low-grade, sustained insults including use of different immunosuppressants such as calcineurin-inhibitors has a significant effect on renal health in the pLT population [6].

Liver transplantation also has a profound impact on the psychological status of the recipient [7]. Young adults, who undergo liver transplantation in childhood, are faced with multiple challenges compared to their peers. The state of chronic physical illness present from a young age may lead to a distorted psychosocial experience of normality and perception of quality of life [8,9].

The long-term functional outcome of these children is increasingly more important. Studies have shown that children who undergo liver transplantation tend to show low average or abnormal scores on cognitive and behavioral tests [10]. The child’s neurodevelopment is likely affected by the underlying disease and long waitlist time, but transplantation does not always correct this impairment [11]. Alongside this, the poor health-related quality of life and prevalence of mental health disorders can lead to an ongoing burden of disease despite transplantation [1].

The United States Society of Pediatric Liver Transplantation (SPLIT) registry evaluated the health status of children alive at 10-years post-liver transplantation [12]. 167 survivors were examined with only 32% achieving an “ideal profile” which was defined by first allograft, stable monotherapy immunosuppression, adequate growth and absence of secondary side effects of immunosuppression. Growth was affected in 23% of patients, whilst 9% had developed Stage 2 chronic kidney disease. Patients had a lower quality of life score, with 14% reporting a generic health-related quality of life value of >2 standard deviations below that of a matched health population.

Whilst long-term outcomes may vary across different geographical locations, the general themes remain the same [13,14]. These long-term issues include graft disease, side effects of immunosuppression, poor growth and metabolic syndrome, and the psychosocial impact of transplantation as they transition to adult care. Few reports have addressed 20-year pLT survivors, and even fewer have focused on the psychosocial outcomes of these survivors [13,15,16]. The aim of this study therefore is to assess the renal function, growth and psychosocial outcomes including mental health, education and employment, substance abuse and adherence in a cohort of children with a median follow-up of 20 years post-transplantation.

2. Methods

A single-center study, based at King’s College London, United Kingdom was performed to evaluate 20-year pLT survivors. The study group consisted of patients who underwent pLT under the age of five, between 1985 and 2004 and survived up to at least 10 years post-transplantation with normal liver biochemistry. We chose this subset of patients with normal graft function at 10 years, to demonstrate the impact of transplantation on the psychological outcomes, growth and end-organ health of these recipients a further 10 years on.

Data was entered into a centralized database on a password-encrypted computer. Data collection of pre-transplant demographics included indications for transplant, age of recipient at liver transplantation, gender, post-transplant details explored included biliary complications, hepatic artery and portal vein complications and immunosuppression regimens used. Data was retrieved from medical records (both paper and electronic records). A structured proforma was used to aid systematic data collection. Study received institutional regulatory approval.

Behavioral and mental health data was obtained from the Integrating Mental and Physical Healthcare: Research, Training and Services (IMPARTS) questionnaire [17]. The IMPARTS questionnaire is a web-based screening system, routinely used by a multidisciplinary team in the transition clinics to collate data on mental health. As part of clinical practice, all young people who then screened positive for possible major depressive disorders or generalized anxiety disorders were offered referral to a clinical psychologist. The IMPARTS system comprises of customized measures for the adolescent population, including Patient Health Questionnaire (PHQ9) and Generalized Anxiety Questionnaire (GAD7) [17]. Data on behavioral and mental health issues was also extracted from electronic patient letters from the multidisciplinary team. Data on substance use, education and work status and adherence in the sample was retrieved from electronic patient notes and clinical letters. Heavy alcohol consumption was defined as drinking twice the recommended daily limit on the heaviest drinking day [18].

Data on renal function was obtained from laboratory tests. Values of cystatin-C and creatinine were documented in a pre-specified proforma. Estimated Glomerular Filtration Rate (eGFR) was calculated using the Creatinine-based “bedside Schwartz” equation and the Grubb formula for cystatin-C based equation. Both the formulas are validated by the National Kidney Foundation for pediatric patients. Weight and height measurements were collected from electronic health records as part of routine screening during follow-up. BMI was calculated as the weight (in kilograms) divided by the height squared (in meters).

We collected data on medication adherence based on ratings given by the attending physician after consultation with the patient. We defined good adherence as medications taken >80% of the time, moderate adherence as 50–80% of the time and poor adherence when medication was taken <50% of the time.
Institutional ethical approval was granted by the National Research Ethics Committee (REC: 15-LO-1258). The Institutional Audit Committee also permitted data collection of the surgical and medical outcomes of the patients at this institution and review of our current practice compared to the national standards. As part of the IMPARTS study, we received research ethical approval for data collection on the psychosocial outcomes of patients through the screening interface (REC: 12-SC-0422).

Data was analyzed using SPSS Statistics software for MAC (IBM Analytics, Florida, USA) and Prism (GraphPad, La Jolla, California, USA). Demographic data was analyzed using descriptive statistics, including absolute numbers (n), percentages, mean, median, standard deviation (SD), and 25 and 75% interquartile range. Data was tested for normality using the Shapiro-Wilk test. Indications for transplant, pre and post-transplant complications, psychosocial outcomes and adherence were expressed as percentages of a whole. All variables assumed Gaussian distribution and t-tests were used to analyze difference between mean eGFR based on cystatin-C and creatinine values. Bland and Altman analysis was used to identify any systematic difference between the formulas used for calculation of eGFR. A two-tailed p-value of <0.05 was considered statistically significant.

3. Role of funding

This study received no funding.

4. Results

Between 1985 and 2004, 585 pediatric patients received liver transplants in our center. The study cohort was selected from patients who had liver transplant before five years of age and survived to 10 years with normal graft function (liver enzymes up to 1.5 times of the normal value) (Fig. 1) and consented for a liver biopsy as part of the study. Eighty-four patients met the study criteria and were included in this study.

The median age at transplantation was 1.3 years (IQR 0.7–3.3 years) and 44% (37/84) were female (Table 1). The median follow-up duration of these patients was 20.2 years (18.0–23.5). Of our patient cohort, 31% (26/84) are now in transition clinics and 50% (42/84) in adult follow-up clinics.

The most common indication for pLT was biliary atresia 51% (43/84) (Table 2). Results of main post-operative complications are shown in Table 3. We report 19% (16/84) vascular complications; 7% (6/84) with hepatic artery thrombosis and 12% (10/84) with portal vein thrombosis. Until 1998, all patients were commenced on cyclosporine and were converted to tacrolimus if they had an episode of allograft rejection. Thereafter, tacrolimus became the first line drug. 33% (28/84) of patients had acute rejection episodes and 21% (18/84) had chronic rejection (Table 3). Two deaths (2%) occurred in the late transplant phase (>10 years). Late graft loss occurred in 7% (6/84), 10 years or more after the initial transplantation.

This cohort demonstrated a mean serum creatinine of 59.6 μmol/L (SD 21.6), and mean cystatin-C of 0.9 mg/l (SD 0.6). When using

![Fig. 1. Liver Biochemistry of each patient included in the study. All patients had normal graft function, with liver enzymes within 1.5x of the upper limit of normal. Vertical lines represent mean with standard deviation. Horizontal lines represent the 1.5x upper limit of normal for each measure.](image-url)
Cystatin C for eGFR calculation, renal impairment (defined as eGFR < 90 ml/min/1.73 m²) was more prevalent (23%, 19/84) compared to eGFR using serum creatinine (11%, 9/84) ($p = 0.0001$) (Fig. 2). All other patients had eGFR above 90 ml/min/1.73 m². None of the patients were on dialysis or received kidney transplants. Bland and Altman analysis test agreement between the Schwartz formula for creatinine and Grubb formula for cystatin-C demonstrated sufficient bias with a mean difference of +25% with a trend in overestimation of the eGFR by Schwartz formula. Analysis using t-tests of the immunosuppressive treatments for eGFR (cysC) showed no significant difference between cyclosporin based immunosuppression versus patients with a tacrolimus based regime in our patient cohort ($p = 0.07$) as shown in Fig. 3.

We also evaluated body mass index (BMI) at median 20 years post-transplantation. The mean BMI was 20.4 (SD +/- 5.0). 8% (7/84) patients had a BMI of > 25, three of whom had a BMI of > 30. None of our patients were on antihypertensive medications. None of the patients had a diagnosis of diabetes mellitus.

Mental health disorders were common, occurring in 26% (22/84) (Fig. 4). Depression was seen in 12% (10/84) of patients, whilst

Table 1
Demographic of Study Population.

|                         | n = 84 |
|-------------------------|--------|
| Age at Transplant (range)| 1.3 (0.7 – 3.3) |
| Duration of follow-up (range)| 20.2 (18.0 – 23.5) |
| Male/Female              | 47/37  |

Table 2
Indications for Transplantation.

| Indications for Transplantation                  | Number, n | %   |
|-------------------------------------------------|-----------|-----|
| Biliary atresia                                 | 43        | 51.2|
| Progressive Familial Intrahepatic Cholestasis   | 7         | 8.3 |
| Acute Hepatic Failure (Indeterminate Aetiology)  | 4         | 4.8 |
| Autoimmune liver disease                        | 4         | 4.8 |
| Hepatoblastoma                                  | 4         | 4.8 |
| Idiopathic Neonatal Hepatitis                   | 1         | 1.2 |
| Metabolic disorders                             | 3         | 3.6 |
| Alpha 1-antitrysin Deficiency                   | 2         | 2.4 |
| Delta 3-oxosteroid 5-beta Reductase deficiency  | 2         | 2.4 |
| Wilson’s Disease                                | 14        | 16.7|
| Others                                          |           |     |

Table 3
Post-operative Complications.

| Post-operative Complications          | Number | %   |
|---------------------------------------|--------|-----|
| Biliary and Vascular Complications    |        |     |
| Biliary Complication                  | 9      | 10.7|
| Hepatic Artery Thrombosis             | 6      | 7.1 |
| Portal Vein Thrombosis                | 10     | 12.0|
| Medical Complications                 |        |     |
| Acute Rejection                       | 28     | 33.3|
| Chronic Rejection                     | 18     | 21.4|
| Denovo hepatitis                      | 13     | 15.5|
| Others                                |        |     |

Fig. 2. Renal function of the patients based on estimated glomerular filtration rate based on creatinine, eGFR(crea) and cystatin-C, eGFR(cysC). Significant difference in mean eGFR based on cystatin C compared to creatinine. Vertical lines represent mean with standard deviation. * Represents a $p$-value that is significant.

Fig. 3. Immunosuppressive treatments and impact on estimated glomerular filtration rate based on cystatin-C, eGFR(cysC). No significant difference found between different immunosuppressive regimes. Each bar represents mean, with vertical lines representing standard deviation.
anxiety including social anxiety and panic attacks occurred in 7% (6/84). Two patients had both depression and anxiety. Attention deficit hyperactivity disorder and autism were present in two patients respectively, whilst one patient suffered from obsessive-compulsive disorder and self-harming behavior. Learning difficulties were common, occurring in 13% (11/84); a further 11% (10/84) were unable to work or continue studies due to health concerns. In this cohort, 29% (24/84) were employed (full time/ part time), 38% (32/84) in higher education and 7% (6/84) were still in school.

Incidence of tobacco smoking was 10% (8/84) – lower than the UK national average of 17% for an age-matched cohort [19]. Excessive alcohol consumption was 4% (3/84) - lower than the national average of 20% [18]. From our patient cohort, 7% (6/84) were married and 4% (3/84) had successful pregnancies. One patient had an early miscarriage at 10 weeks.

Adherence was reported to be good in 67% (56/84) followed by moderate adherence in 17% (14/84) and poor adherence in 8% (7/84) (Fig. 5). In our patient cohort, only 26% (22/84) had a composite profile of “meaningful survival” (Table 4). This was characterized by survival to median of 20-years, presence of normal liver biochemistry, no renal dysfunction, normal BMI, no mental health disorder and were in education or employment and had good adherence of >80%.
tend to overestimate renal function in children [26]. Cystatin-C has
these studies. Most studies use a calculated eGFR based on serum cre-
ments and therefore the need to closely monitor these children with a reli-
with renal dysfunction with standard immunosuppression protocols, the numbers in each cohort were small
change in their Intelligence Quotient as compared to pre-transplant.
that as a group, children post-transplantation do not show much
not always signify a cure, instead it is another form of a chronic ill-
with infection or rejection [29]. Up to 30% of our cohort of
experience a sense of elation. The role of parents as carers whilst
 medicaments on neurocognitive functioning and physical health at
to being overlooked [22,23]. In this study, we reviewed some of the long-term outcome metrics of pLT.
Chronic renal failure is an important long-term complication post-
the main contributors are nephrotoxic effects of the
calcineurin inhibitors; namely cyclosporine and tacrolimus, as well
as a primarily renal pathology of the underlying liver diagnosis and
the use of nephrotoxic antibiotics. Several pediatric studies have
shown rates of renal failure ranging from 0% to 32% [6,24,25]. This
wide range is likely due to the individual immunosuppressive regi-
mens and the different methods used to determine renal function in
these studies. Most studies use a calculated eGFR based on serum creat-
ine, but these methods have been shown to be inaccurate and
tend to overestimate renal function in children [26]. Cystatin-C has
been increasingly used as an easy and reliable marker of renal func-
tion to determine deterioration of kidney function. Our center has
shown good correlation between cystatin-C levels and measured
eGFR, especially in children after liver transplantation in the short term [27]. We show a significant discrepancy of a cystatin C-based equation compared to creatinine-based equations in the calculation of eGFR and identification of patients with renal failure.
Our data comprises of a large 20-year follow-up study of pLT patients who received liver transplant before school age and these results are consistent with other published studies which report roughly 30% of patients with chronic renal failure >10 years post-
liver transplant [6]. We demonstrate a prevalence of 23% of patients
with renal dysfunction with standard immunosuppression protocols and therefore the need to closely monitor these children with a reli-
able method to determine eGFR.
Although we did not show significant difference between immu-
nosuppressive protocols, the numbers in each cohort were small
with only ten patients on cyclosporine-based regimes. Guidelines on
how to modify immunosuppression drugs once renal dysfunction is
detected are needed. There is contradictory evidence on the impact
cyclosporine compared to tacrolimus treated patients on renal dys-
function. Exposure to immunosuppressive treatments over time also
matters [25]. Newer strategies through randomized studies using
less nephrotoxic drugs are still needed.
The Health Survey for England 2019, showed that 37% of 16–24
years old were overweight or obese, compared to the 8% in our
cohort (Table 5). After transplantation, children with adequate graft
function tend to recover their weight gain in spite of prior malnutri-
tion. Linear growth tends to improve, but catch-up growth can be
variable depending on the underlying etiology of the pre-transplant
state and accumulative steroid use. Whilst we did not analyze specific
risk factors for obesity, studies have suggested the following as risk
factors including: patient’s BMI before transplantation, higher accumu-
lative dose of prednisolone and episodes of acute rejection [28].
With this in mind, adequate nutritional management is important
with the increased success of pLT programs.
Following successful transplantation, many children and families
experience a sense of elation. The role of parents as carers whilst
their child awaits the transplant is relinquished to the liver team and
intensive care staff once the transplant occurs. This period of “cease-
fire” is then quickly diminished by the child’s first episode of complic-
ution with infection or rejection [29]. Up to 30% of our cohort of
patients experienced acute rejection whilst surgical and vascular
complications occurred in 1 in 5 of our patient cohort. The post-trans-
plant period is a roller coaster of emotions for both the parent and
child.
The Mental Health Report in 2014 reported that 19.7% of people in
the UK aged 16 and older showed symptoms of anxiety and depres-
sion [30]. We report a similar proportion with anxiety and depression (Table 5). The emotional reaction brought about by the frustration of not being “cured” by the transplant is well known [31]. For children and their families, accepting the limitation that the transplant does not always signify a cure, instead it is another form of a chronic ill-
ness, which may be easier to manage, can be a significant challenge.
The ability to return to a near normal life is an important gauge
for the success of a medical intervention [13]. Our data suggests 74% of
our cohort were in age-appropriate education or in employment.
Twelve percent were unable to work or study despite ongoing good
graft function. When compared to data from the Office of National
Statistics, 11.3% of the UK population (aged 16–24 years) were not in
education, employment or training in 2018 (Table 5) [32]. Public
Health England reported that in 2018, 33.9 per 1000 (3.4%) of the UK
population of children had learning difficulties [33]. This was signifi-
cantly lower than the described number of children with learning
disabilities, which was reported to be as high as 13% (Table 5). A
number of studies have investigated the cognitive abilities of children
pre- and post-transplantation [34,35]. These studies have suggested
that as a group, children post-transplantation do not show much
change in their Intelligence Quotient as compared to pre-transplant.
Risk-taking behavior is a common theme in the adolescent popu-
lation but may be easily brushed aside during the late post-transplant
stage, when substance abuse tends to begin. According to the Office
for National Statistics the number of 18 to 24 year olds who were
smokers in 2018 was 16-8% [19]. We report smoking in roughly 10% of
our patient cohort, lower than that of the UK national average
(Table 5). Similarly with heavy alcohol consumption, the UK data sug-
gests a reduction in number of young people between 16 and 24
years who are heavy drinkers, but the numbers are still as high as
18% in this cohort [18]. We report a significantly lower proportion of
heavy drinking of only 3-6% (Table 5). Substance abuse is generally
lower in our patient cohort, which may be secondary to our transition
clinics (31% in transition clinics), where risk-taking behavior is
reviewed and discussed.
Only a quarter of our cohort had achieved a composite profile of’reasonable survival’. For our survivors to achieve a normal life span

5. Discussion
Advances in the field of pLT mean that short-term complications have
decreased and survival rates have improved [20]. However, a
correlate of this success is that long-term effects of transplantation
are more evident as our pre-school age recipients approach over 20-
years post-transplantation. This age group is especially important, as
the first couple of years of life are crucial to a child’s brain develop-
ment for the formation of cognitive, social and emotional health [21].
The impact of severe disease, surgical intervention, anesthetia and
medications on neurocognitive functioning and physical health at
this age cannot be overstated [22,23]. In this study, we reviewed some of the long-term outcome metrics of pLT.
Table 4
Composite Analysis Strategy Approach at 20-years.

| Variable                                      | Number of patients, n (%) |
|-----------------------------------------------|----------------------------|
| Survival to median 20-years                   | 82 (97.6)                  |
| Normal renal function (according to Cystatin-C eGFR) | 65 (77.4)                  |
| Normal BMI                                    | 77 (91.7)                  |
| No mental health disorder                     | 62 (73.8)                  |
| In education or employment                    | 62 (73.8)                  |
| Good adherence                                | 56 (66.7)                  |

Table 5
20-year outcomes compared to national data (16–24 year olds).

| Outcomes                        | 20-years post-transplant | National Data (16–24 year olds) |
|---------------------------------|--------------------------|--------------------------------|
| BMI >25                         | 8.3%                     | 37.0%                         |
| Anxiety and depression          | 19.1%                    | 19.7%                         |
| Not in education or employment  | 26.2%                    | 11.3%                         |
| Learning difficulties           | 12.1%                    | 3.4%                          |
| Smoking                        | 9.5%                     | 16.8%                         |
| Heavy alcohol consumption      | 3.6%                     | 18.0%                         |
and quality of life, we must address the challenges of side effects of medication, long-term graft failure and the adverse behavioral, emotional and social effects of chronic illness. The early identification of these potential health hazards through transition clinics provides a concerted and coordinated effort to managing these recipients.

This study shows that even in this relatively large cohort of patients with good graft function post-transplantation, the impact of transplantation on psychosocial and physical health is significant. Though we did not use specific questionnaires for education and employment and substance abuse, there was clear documentation in patient notes by clinicians to extract this data. Medication adherence was assessed through a structured consultation with the clinician, which was convenient and efficient. However, we recognize that this may be subject to recall and response bias, which may decrease accuracy and validity. The lack of standardization of data input, may however limit comparability of our findings.

Whilst we still have much ground to cover in the scientific and medical understanding of pLT, some existing issues of care remain: improve current treatment modalities to reduce toxicity, address the psychosocial impact and reduce the economic burden secondary to the reduced long-term quality of life in these childhood survivors.

Our data suggests that late mortality and late graft loss are uncommon, possibly secondary to better surgical techniques and multidisciplinary long-term follow up in our center. However, pLT recipients continue to face multiple challenges affecting their long-term physical health. The impact of lifelong immunosuppression on renal health and nutrition are pertinent issues that require emphasis as these children transition from pediatric to adult services. We show a comparable but alarming number of children with renal dysfunction on standard immunosuppression protocols 20-years post-transplantation and the immediate need to address these issues.

In children, optimizing quality of life post-transplantation is crucial, as their potential life span following liver transplantation continues to improve. Our cohort shows relatively good psychological outcomes post-transplantation. The integration of psychosocial evaluation through IMPARTS to our routine practice has been an important step in assessing the health status of these children.

Therefore, in conclusion, despite favorable survival outcomes, based on a long post-transplantation follow-up period, only a limited number of recipients achieve an overall composite profile of ‘meaningful survival’. In facing the future, the onus is on us, as clinicians, to improve our current understanding of these complications, through early detection and collaborative multi-center efforts, so our patients can have a meaningful survival.

Statement of contribution

SV contributed to the research design, writing the paper, performance of the research and data analysis. SV, LNS, MD and AD had full access to the data. MD, JD and LNS contributed to data acquisition and writing the paper. MD, MS, AV, HVM, MR and NH contributed to revising the draft. AD contributed to the conception and design of the work, data analysis, writing the paper and final approval of the paper.

Declaration of Competing Interest

LNS received a PhD grant from CAPES- Brazil. All other authors declare no conflicts of interest.

Funding source

The authors received no financial support for the research, authorship and publication of this article.

Data sharing statement

The data that support the findings of this study are available on request from the corresponding author, AD.

References

[1] Duffy JP, Kao K, Ko CY, Farmer DG, McDarmid SV, Hong JC, et al. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg 2010;252(4):652–61.
[2] Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, et al. Unacceptable failures: the final report of the lancet commission into liver disease in the UK. Lancet 2020;395(10219):226–39.
[3] Vazquez NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr 2013;16(4):207–18.
[4] Farmer DG, Venick RS, McDarmid SV, Ghobrial RM, Gordon SA, Yerissi H, et al. Predictors of outcomes after pediatric liver transplantation: an analysis of more than 800 cases performed at a single institution. J Am Coll Surg 2007;204(5):504–14 discussion 14-6.
[5] Weber ML, Ibraham HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 2012;18(11):1290–301.
[6] Hambardj J, Ranchin B, Albouy L, Liikku A, Hadj-Haissa A, Richet C, et al. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation 2008;86(8):1028–34.
[7] Bradford R. Children’s psychological health status – the impact of liver transplantation: a review. J R Soc Med 1991;84(9):550–3.
[8] Parmar A, Vandreil SM, Ng VL. Health-related quality of life after pediatric liver transplantation: a systematic review. Liver Transpl 2017;23(3):361–74.
[9] Feldman AG, Neighbors K, Mukherjee S, Rak M, Varji JV, Alonso EM. Impaired physical function following pediatric LT. Liver Transpl 2016;22(4):495–504.
[10] Alshar S, Porter M, Barton B, Stormon M. Intellectual and academic outcomes after pediatric liver transplantation: relationship with transplant-related factors. Am J Transpl 2018;18(9):2229–37.
[11] Mohammad S, Alonso EM. Approach to optimizing growth, rehabilitation, and neurodevelopmental outcomes in children after solid-organ transplantation. Pediatr Clin North Am 2010;57(2):539–57 table of contents.
[12] Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varji JV, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr 2012;160(5):620–6 e3.
[13] Martinielli J, Hahes B, Majed L, Gaertier C, Gonzales E, Linglart A, et al. Long-term outcome of liver transplantation in childhood: a study of 20-year survivors. Am J Transpl 2018;18(7):1680–9.
[14] Cuenca AG, Yeh H. Improving patient outcomes following pediatric liver transplant: current perspectives. transplant research and risk management. 2019 11:69–78.
[15] Jain A, Singh A, Fontes P, Mazaregio G, DeVera ME, Caccarelli T, et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. Transplantation 2011;91(9):1025–30.
[16] Mohammad S, Hormaza L, Neighbors K, Boone P, Tierney M, Azzam RK, et al. Health status in young adults two decades after pediatric liver transplantation. Am J Transpl 2012;12(6):1446–95.
[17] Hames A, Matcham F, Joshi D, Heneghan MA, Dhawan A, Heaton N, et al. Liver transplantation and adolescence: the role of mental health. Liver Transplant 2016;22(11):1544–53.
[18] NG Fat L, Shelton N, Cable N. Investigating the growing trend of non-drinking among young people; analysis of repeated cross-sectional surveys in England 2005–2015. BMC Public Health 2018;18(1):1090.
[19] Statistics OH. Adult smoking habits in the UK. 2017–2018. 2018.
[20] Manoochehr Karjoo MAK, Sarveazad Arash, Saeidi Masumeh. Short and long term complications after pediatric liver transplantation: a review and literature. Int J Pediatr 2017;5(12):e3337–46.
[21] Dennis M, Speigler BJ, Jarunek BJ, Bigler ED, Snead OC, Fletcher JM. Age, plasticity, and homeostasis in childhood brain disorders. Neurosci Biobehav Rev 2013;37:2760–73 10 Pt 2.
[22] Caulde SE, Katzenstein JM, Karpen SJ, McLain VA. Language and motor skills are impaired in infants with biliary atresia before transplantation. J Pediatr 2010;156(6):e36–40 e1.
[23] Gilmour SM, Sorensen LG, Anand K, Yin W, Alonso EM, Consortium SR. School outcomes in children registered in the studies for pediatric liver transplant (SPLIT) consortium. Liver Transpl 2010;16(9):1041–8.
[24] Bishop JR, Burniston MT, Barnfield MC, Stringer MD, Prasad R, Davison SM, et al. Renal function evaluated by measured GFR during follow-up in pediatric liver transplant recipients. Pediatr Transplant 2009;13(1):96–103.
[25] Herzig D, Martin S, Turpin S, Alvarez F. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006;81(5):672–7.
[26] Bharat W, Manihoft C, McIndee BW, Pollock-Batziw D, Dipchand AJ. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr Transplant 2009;13(1):111–8.
[27] Samyn M, Cheeseman P, Bevis L, Taylor R, Samaroo B, Buxton-Thomas M, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in

S. Vimalesvaran et al. / EClinicalMedicine 38 (2021) 100987 7
children with liver disease and after liver transplantation. Liver Transpl 2005;11 (3):344–9.

[28] Wawrzynowicz-Syczewska M, Karpinska E, Jurczyk K, Laurans I, Boron-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transpl 2009;14(3):45–50.

[29] Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the Liver in Humans. Surg Gynecol Obstet 1963;117:659–76.

[30] Mental Health Bulletin, Annual Report - 2013-14 [Internet]. 2014. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-bulletin/mental-health-bulletin-annual-report-2014-15.

[31] Bradford R, Tomlinson L. Psychological guidelines in the management of paediatric organ transplantation. Arch Dis Child 1990;65(9):1000–3.

[32] Statistics OFN. Employment in the UK. 2018.

[33] England P.H. Learning disability profiles. 2018.

[34] Andrews W, Fyock B, Gray S, Coln D, Hendrickse W, Siegel J, et al. Pediatric liver transplantation: the Dallas experience. Transpl Proc 1987;19(4):3267–76.

[35] Stewart SM, Uauy R, Waller DA, Kennard BD, Benser M, Andrews WS. Mental and motor development, social competence, and growth one year after successful pediatric liver transplantation. J Pediatr 1989;114:574–81 Pt 1.